FDA inspection
Boehringer Ingelheim Pharmaceuticals, Inc.: FDA inspection ending May 2, 2024
FDA inspection 1235545 · No Action Indicated (NAI) · Ridgefield, CT
Key facts
| Inspection ID | 1235545 |
|---|---|
| Firm | Boehringer Ingelheim Pharmaceuticals, Inc. |
| FEI number | 1219205 |
| Address | 900 Ridgebury Rd |
| City | Ridgefield |
| State | CT |
| ZIP | 06877-1058 |
| Fiscal year | 2024 |
| Inspection end date | May 2, 2024 |
| Classification | No Action Indicated (NAI) |
| Project area | Human Cellular, Tissue, and Gene Therapies |
| Product type | Biologics, Drugs |
At a glance
- None Citations
- None Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data